Insulin resistance and substrate utilization in human endotoxemia.
about
Insulin: a wonder drug in the critically ill?An inflammatory cascade leading to hyperresistinemia in humansAcute low-dose endotoxin treatment results in improved whole-body glucose homeostasis in mice.Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.Mechanisms of inflammatory responses in obese adipose tissue.Metabolic response to endotoxin in vivo in the conscious mouse: role of interleukin-6.Comparative analysis of the human hepatic and adipose tissue transcriptomes during LPS-induced inflammation leads to the identification of differential biological pathways and candidate biomarkers.Lipopolysaccharide increases resistin gene expression in vivo and in vitro.Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease.Periodontal disease is associated with gestational diabetes mellitus: a case-control studyPeriodontitis and diabetes interrelationships: role of inflammation.Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice.Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shockGSK3β is increased in adipose tissue and skeletal muscle from women with gestational diabetes where it regulates the inflammatory responseEvaluating the impact of sequencing depth on transcriptome profiling in human adiposeExogenous glucose administration impairs glucose tolerance and pancreatic insulin secretion during acute sepsis in non-diabetic miceAdipose inflammation, insulin resistance, and cardiovascular diseaseExercise-induced AMPK and pyruvate dehydrogenase regulation is maintained during short-term low-grade inflammationIL-1 resets glucose homeostasis at central levelsActivation of innate immunity modulates insulin sensitivity, glucose effectiveness and pancreatic β-cell function in both African ancestry and European ancestry healthy humansRole of inhibitory κB kinase and c-Jun NH2-terminal kinase in the development of hepatic insulin resistance in critical illness diabetesRole of tissue macrophages in the development of critical illness diabetesFractalkine is a novel human adipochemokine associated with type 2 diabetesInflammation modulates human HDL composition and function in vivo.Relationship between resistin level in serum and acute coronary syndrome or stable angina pectoris.Lipopolysaccharide induces a downregulation of adiponectin receptors in-vitro and in-vivoA human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial.Chronic exposure to low doses of lipopolysaccharide and high-fat feeding increases body mass without affecting glucose tolerance in female rats.Adipose genes down-regulated during experimental endotoxemia are also suppressed in obesity.Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia.Direct control of hepatic glucose production by interleukin-13 in mice.Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the blood-brain barrier.Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolismRace and gender variation in response to evoked inflammationAcute, muscle-type specific insulin resistance following injury.From therapy to experimental model: a hundred years of endotoxin administration to human subjects.Molecular mechanisms involved in the bidirectional relationship between diabetes mellitus and periodontal disease.Inflammation during obesity is not all bad: evidence from animal and human studies.Gene profiling of human adipose tissue during evoked inflammation in vivo.Insulin signaling in skeletal muscle and liver of neonatal pigs during endotoxemia.
P2860
Q24796369-020C5EDB-2B3A-4CA7-8095-354EE250927DQ24796813-F0A08B0B-443A-4482-92B2-9FAD942128DAQ30274807-67EF0C91-660E-4F3C-86AD-FCBB0DD4632FQ33556498-BB34A45A-AA9A-4D20-9573-D89E7EB1050BQ33699810-B40A8916-B153-45EC-9DB1-E13F7EEB26E1Q33926996-524690C8-F472-40DF-AD48-B7B59F3965DCQ34042106-0CFE802C-150B-4CBF-B630-1435E12FBAA4Q34155143-2BB14C51-F97F-41AF-95E3-2136BA719D7AQ34330120-B88FCFEA-0570-4F42-A6D4-0A6C65AB1D09Q34446849-80458A4C-7D66-4199-98F7-690A6A424A8FQ34557654-3A87507A-C01F-463A-9504-C1FB9AFAF11EQ34615398-377737DD-0D73-40E0-B4A9-98983D9401D6Q34697264-BEFD846F-C1CF-4DCF-A4E2-9992AE8265BBQ34776721-7BB8AC3F-1F0E-4FF5-BE43-A59FBC4B7A59Q34796197-6A438D89-AFA4-4197-A5A4-875E712B465EQ34797463-F0E490AA-584C-4E73-9635-4961C2C88057Q34931211-B2410979-5D1A-435E-91FE-3D94A24C55AAQ34947306-F7D598D1-5EF7-4C51-A0C6-52D9BE8EDAFAQ35127624-1B085FFD-DAF4-4EF6-8128-9D36B648986CQ35137615-025AF27C-7D60-4A13-B986-026DB36DBFACQ35216722-E322CD40-924F-43D6-8710-D0FF61177E58Q35612847-C5F95BC7-E0AB-4DA3-901E-F4CA0C28EDC5Q35796996-1F64AE75-31F0-4002-A1D9-9140376FB976Q35992445-CABA1A2F-2BB9-4154-9EF4-E85EE26EB057Q36178268-A9713035-C8D0-473F-AFAC-7CF4A0BEB372Q36304715-BD3C82D3-6822-411B-B34D-EF60F99F2007Q36335205-56BA8EE8-FF4B-4E77-B4E0-C0B60F917682Q36357486-E88878ED-C3F3-4564-80EA-2B916AF6B9BBQ36361395-AC38D120-C987-4A20-918D-84523980B786Q36366326-17A2B704-C0FC-49C6-A8DD-73DC9636FFC2Q36497258-961A5B17-CA84-494B-9199-3462B2044A46Q36513140-FD6A2E0C-F671-4098-AEEE-67C71A6BF1F4Q36538532-DBD5576B-E61C-43D1-B739-92C3B922A152Q36794209-867D0D61-12C8-4819-8168-E7E862C0CBFFQ36972592-047DAE42-63C9-421D-8492-8CF58758A6C7Q36994694-34BC293D-7EE7-433B-887C-63D4EAF52113Q37158663-8B7919B9-B393-4481-8BE5-564271A8555DQ37174503-09FE82E9-FA23-497F-9421-37930F8B6636Q37360466-2E466504-DAA9-49FD-8B8F-45BDB8BC450DQ37414140-9E43DA7B-EA71-44DA-9D54-AB1E49AAA170
P2860
Insulin resistance and substrate utilization in human endotoxemia.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Insulin resistance and substrate utilization in human endotoxemia.
@en
type
label
Insulin resistance and substrate utilization in human endotoxemia.
@en
prefLabel
Insulin resistance and substrate utilization in human endotoxemia.
@en
P2093
P356
P1476
Insulin resistance and substrate utilization in human endotoxemia.
@en
P2093
P304
P356
10.1210/JCEM.85.10.6914
P407
P577
2000-10-01T00:00:00Z